Comparative Pharmacology
Head-to-head clinical analysis: CAPOTEN versus DEAPRIL ST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOTEN versus DEAPRIL ST.
CAPOTEN vs DEAPRIL-ST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
ACE Inhibitor
ACE Inhibitor